

HALOZYME THERAPEUTICS INC  
Form 8-K  
September 05, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): September 5, 2018**

**HALOZYME THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**11388 Sorrento Valley Road, San Diego, California**

**001-32335**  
**(Commission**

**File Number)**

**88-0488686**  
**(IRS Employer**

**Identification No.)**

**92121**

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (858) 794-8889

**Not Applicable**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

The Halozyme Therapeutics, Inc. ( Halozyme ) slide presentation attached hereto as Exhibit 99.1 (as well as the information contained therein) provides a corporate update on certain strategic programs and is expected to be used in presentations to interested parties, including analysts and stockholders.

This information is being furnished pursuant to Item 7.01 of this Current Report on Form 8-K (the Report ) and shall not be deemed to be filed for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by Halozyme, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference. This Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed pursuant to Regulation FD.

Please refer to the presentation attached hereto as Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.

**Item 9.01. Financial Statements and Exhibits.**

Exhibits

Exhibit

No.	Description
99.1	<u>Halozyme Therapeutics, Inc. corporate update presentation dated September 5, 2018</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Halozyme Therapeutics, Inc.

September 5, 2018

By: /s/ Harry J. Leonhardt, Esq.

Name: **Harry J. Leonhardt, Esq.**

Title: **Senior Vice President, General Counsel,**

**Chief Compliance Officer and Corporate  
Secretary**